These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 19571282

  • 1. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R.
    N Engl J Med; 2009 Jul 02; 361(1):40-51. PubMed ID: 19571282
    [Abstract] [Full Text] [Related]

  • 2. ACE-I and ARBs in early diabetic nephropathy.
    Mauer M, Zinman B, Gardiner R, Drummond KN, Suissa S, Donnelly SM, Strand TD, Kramer MS, Klein R, Sinaiko AR.
    J Renin Angiotensin Aldosterone Syst; 2002 Dec 02; 3(4):262-9. PubMed ID: 12584670
    [Abstract] [Full Text] [Related]

  • 3. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Katavetin P, Katavetin P.
    N Engl J Med; 2009 Oct 01; 361(14):1410-1; author reply 1411. PubMed ID: 19802919
    [No Abstract] [Full Text] [Related]

  • 4. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Tamsma JT.
    N Engl J Med; 2009 Oct 01; 361(14):1410; author reply 1411. PubMed ID: 19797291
    [No Abstract] [Full Text] [Related]

  • 5. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb 01; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 6. The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study.
    Klein R, Moss SE, Sinaiko AR, Zinman B, Gardiner R, Suissa S, Donnelly SM, Kramer MS, Goodyer P, Strand T, Mauer M.
    Ophthalmology; 2006 Dec 01; 113(12):2231-6. PubMed ID: 16996597
    [Abstract] [Full Text] [Related]

  • 7. Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
    Tan F, Mukherjee JJ, Lee KO, Lim P, Liew CF.
    Singapore Med J; 2010 Feb 01; 51(2):151-6. PubMed ID: 20358155
    [Abstract] [Full Text] [Related]

  • 8. Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.
    He YM, Feng L, Huo DM, Yang ZH, Liao YH.
    Nephrology (Carlton); 2013 Sep 01; 18(9):605-14. PubMed ID: 23869492
    [Abstract] [Full Text] [Related]

  • 9. Losartan and enalapril are comparable in reducing proteinuria in children.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C.
    Kidney Int; 2012 Oct 01; 82(7):819-26. PubMed ID: 22739977
    [Abstract] [Full Text] [Related]

  • 10. Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition.
    Juhlin T, Erhardt LR, Ottosson H, Jönsson BA, Höglund P.
    Eur J Heart Fail; 2007 Feb 01; 9(2):191-6. PubMed ID: 16859993
    [Abstract] [Full Text] [Related]

  • 11. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M, Uehara S, Ohta H, Taguchi K, Kemi M, Nishikibe M, Matsumoto H.
    Life Sci; 2004 Jul 02; 75(7):869-80. PubMed ID: 15183078
    [Abstract] [Full Text] [Related]

  • 12. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
    Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, VA NEPHRON-D Investigators.
    N Engl J Med; 2013 Nov 14; 369(20):1892-903. PubMed ID: 24206457
    [Abstract] [Full Text] [Related]

  • 13. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study.
    Reyes-Marín FA, Calzada C, Ballesteros A, Amato D.
    Rev Invest Clin; 2012 Nov 14; 64(4):315-21. PubMed ID: 23227581
    [Abstract] [Full Text] [Related]

  • 14. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N, Zoja C, Corna D, Rottoli D, Gaspari F, Haskell L, Remuzzi G.
    Kidney Int; 2009 Nov 14; 76(9):960-7. PubMed ID: 19625993
    [Abstract] [Full Text] [Related]

  • 15. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, VA NEPHRON-D Investigators.
    Clin J Am Soc Nephrol; 2009 Feb 14; 4(2):361-8. PubMed ID: 19118120
    [Abstract] [Full Text] [Related]

  • 16. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
    Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.
    Clin Exp Nephrol; 2006 Sep 14; 10(3):193-200. PubMed ID: 17009077
    [Abstract] [Full Text] [Related]

  • 17. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C.
    Pediatr Nephrol; 2013 May 14; 28(5):737-43. PubMed ID: 23207876
    [Abstract] [Full Text] [Related]

  • 18. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
    Sjølie AK, Dodson P, Hobbs FR.
    Int J Clin Pract; 2011 Feb 14; 65(2):148-53. PubMed ID: 21235695
    [Abstract] [Full Text] [Related]

  • 19. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
    Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P.
    BMJ; 1988 Oct 29; 297(6656):1092-5. PubMed ID: 2848604
    [Abstract] [Full Text] [Related]

  • 20. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
    Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD.
    Clin J Am Soc Nephrol; 2014 Feb 29; 9(2):295-301. PubMed ID: 24408116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.